Savara (SVRA) Research & Development (2010 - 2026)
Savara (SVRA) reported Research & Development of $23.4 million for Q1 2026, up 22.13% year-over-year from $19.2 million in Q1 2025, and up 11.94% on a QoQ basis from $20.9 million in Q4 2025.
Savara (SVRA) has 17 years of Research & Development data on file, last reported at $23.4 million in Q1 2026.
- Quarterly Research & Development rose 22.13% year-over-year to $23.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85.6 million (up 6.55% YoY) and the FY2025 annual result came in at $81.4 million, up 4.33% from the prior year.
- Research & Development advanced to $23.4 million in Q1 2026 per SVRA's latest filing, from $20.9 million in the prior quarter.
- Across five years, Research & Development topped out at $23.4 million in Q1 2026 and bottomed at $5.7 million in Q1 2022.
- The 5-year median for Research & Development is $16.8 million (2024), against an average of $15.0 million.
- The widest annual swing landed in 2022, when Research & Development retreated 25.1%; it then soared 97.7% in 2024.
- Tracing SVRA's Research & Development over 5 years: stood at $7.6 million in 2022, then jumped by 67.14% to $12.7 million in 2023, then surged by 82.76% to $23.3 million in 2024, then decreased by 10.27% to $20.9 million in 2025, then gained by 11.94% to $23.4 million in 2026.
- Per Business Quant, the three latest SVRA Research & Development figures stand at $23.4 million (Q1 2026), $20.9 million (Q4 2025), and $20.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 23.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.40 Mn |
| Dec 31, 2025 | 20.90 Mn |
| Sep 30, 2025 | 20.59 Mn |
| Jun 30, 2025 | 20.75 Mn |
| Mar 31, 2025 | 19.16 Mn |
| Dec 31, 2024 | 23.29 Mn |
| Sep 30, 2024 | 20.31 Mn |
| Jun 30, 2024 | 17.62 Mn |
| Mar 31, 2024 | 16.81 Mn |
| Dec 31, 2023 | 12.75 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Jun 30, 2023 | 8.91 Mn |
| Mar 31, 2023 | 8.74 Mn |
| Dec 31, 2022 | 7.63 Mn |
| Sep 30, 2022 | 8.15 Mn |
| Jun 30, 2022 | 6.42 Mn |
| Mar 31, 2022 | 5.68 Mn |
| Dec 31, 2021 | 7.62 Mn |
| Sep 30, 2021 | 6.53 Mn |
| Jun 30, 2021 | 7.25 Mn |
| Mar 31, 2021 | 7.59 Mn |
| Dec 31, 2020 | 10.16 Mn |
| Sep 30, 2020 | 5.60 Mn |
| Jun 30, 2020 | 6.08 Mn |
| Mar 31, 2020 | 13.20 Mn |
| Dec 31, 2019 | 8.72 Mn |
| Sep 30, 2019 | 9.58 Mn |
| Jun 30, 2019 | 10.46 Mn |
| Mar 31, 2019 | 10.02 Mn |
| Dec 31, 2018 | 9.86 Mn |
| Sep 30, 2018 | 9.51 Mn |
| Jun 30, 2018 | 9.27 Mn |
| Mar 31, 2018 | 8.54 Mn |
| Dec 31, 2017 | 6.44 Mn |
| Sep 30, 2017 | 4.97 Mn |
| Jun 30, 2017 | 4.16 Mn |
| Mar 31, 2017 | 2.95 Mn |
| Dec 31, 2016 | 3.49 Mn |
| Sep 30, 2016 | 2.14 Mn |
| Jun 30, 2016 | 1.29 Mn |
| Mar 31, 2016 | 7.88 Mn |
| Dec 31, 2015 | -16.79 Mn |
| Sep 30, 2015 | 7.33 Mn |
| Jun 30, 2015 | 7.73 Mn |
| Mar 31, 2015 | 6.04 Mn |
| Dec 31, 2014 | 4.93 Mn |
| Sep 30, 2014 | 5.40 Mn |
| Jun 30, 2014 | 4.82 Mn |
| Mar 31, 2014 | 4.28 Mn |
| Dec 31, 2013 | 3.52 Mn |
| Sep 30, 2013 | 3.10 Mn |
| Jun 30, 2013 | 2.84 Mn |
| Mar 31, 2013 | 3.44 Mn |
| Dec 31, 2012 | 2.11 Mn |
| Sep 30, 2012 | 1.66 Mn |
| Jun 30, 2012 | 2.11 Mn |
| Mar 31, 2012 | 2.21 Mn |
| Dec 31, 2011 | 1.75 Mn |
| Sep 30, 2011 | 2.05 Mn |
| Jun 30, 2011 | 1.34 Mn |
| Mar 31, 2011 | 611,293.00 |
| Dec 31, 2010 | 897,358.00 |
| Sep 30, 2010 | 918,309.00 |
| Jun 30, 2010 | 633,766.00 |